Logo
x

Search

Subscribe Now

 Regulatory

PharmaShots Weekly Snapshots (November 18 – November 22, 2024)

PharmaShots Weekly Snapshots (November 18 – November 22, 2024)

  • November 22, 2024
Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

  • November 22, 2024
GSK’s Arexvy Vaccine Receives the MHLW’s Approval for its Expanded Age Indication to Prevent RSV Disease

GSK’s Arexvy Vaccine Receives the MHLW’s Approval for its Expanded Age Indication to Prevent RSV Disease

  • November 22, 2024
InxMed’s Ifebemtinib Secures the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of KRAS G12C Mutated NSCLC

InxMed’s Ifebemtinib Secures the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of KRAS G12C Mutated NSCLC

  • November 21, 2024
Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

  • November 21, 2024
UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

  • November 21, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.